Shorts

1:08
CMSC 2026: Assessing Biological Disease Activity in MS
2 months ago
by
Darin T. Okuda, MD, FAAN, FANA(+1 more)

1:26
AAIC 2026: Future of Blood-Based Biomarkers for Alzheimer Care
2 months ago
by
Soeren Mattke, MD, DSc(+1 more)

0:55
AAIC 2026: Improving Amyloid Biomarker–Guided Diagnosis in AD
2 months ago
by
Suzanne Schindler, MD, PhD(+1 more)

2:02
RECAP: Neurology News Network - Week of July 25th
2 months ago
by
Louie Pasculli

0:35
Personalizing Communication About Emerging Alzheimer Disease Therapies
2 months ago
by
Betty Tijms, PhD(+1 more)

1:07
Fragile X Syndrome Day 2026: 3 Primary Domains of Symptoms
2 months ago
by
Craig A. Erickson, MD(+1 more)

0:47
World Brain Day 2026: What is the Best Way to Preserve and Maintain Brain Health?
2 months ago
by
Jason A. Cohen, MD(+1 more)

0:44
AAIC 2026: Why Every “Shot on Goal” Matters in Alzheimer Disease Care
2 months ago
by
Louie Pasculli(+1 more)

1:41
SLEEP 2026: Designing Phase 3 Trials for Narcolepsy Type 1
2 months ago
by
Elena Koundourakis, PhD(+1 more)

1:13
SLEEP 2026: Unmet Needs in Pediatric Sleep Medicine
2 months ago
by
Carol Rosen, MD(+1 more)

0:41
AAIC 2026: Where Can Patients Learn About Emerging Alzheimer Disease Therapies?
2 months ago
by
Jeff Dage, PhD(+1 more)

0:58
SLEEP 2026: New Guidance on RLS Management
2 months ago
by
Michael Silber, MBChB(+1 more)

0:53
Symptom Overlap Between Multiple Sclerosis and NMOSD
2 months ago
by
Mitzi Joi Williams, MD

0:50
CMSC 2026: Questioning Targets in MS Treatment
3 months ago
by
Ahmed Obeidat, MD, PhD(+1 more)

1:15
CMSC 2026: Enhancing MS Clinical Trial Impact
3 months ago
by
Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC(+1 more)

0:40
AAIC 2026: Rethinking Patient-Centered Neurology Care Today
3 months ago
by
Mirnova Ceide, MD, MS(+1 more)

0:40
Expanding the Approach to AD Care Beyond Pharmacological Treatments
3 months ago
by
Elizabeth Rhodus, PhD, MS(+1 more)

0:58
RECAP: Neurology News Network - July 12th
3 months ago
by
Louie Pasculli

0:40
AAIC 2026: Characterizing Midlife Brain Health in Retired Soccer Players
3 months ago
by
Caleigh G. Lynch, MSc(+1 more)

1:00
The 2024 MS Diagnostic Criteria: More Than a Definition Update
3 months ago
by
Daniel Ontaneda, MD, PhD(+1 more)

0:35
Building a Path Toward Neuropathy Reversal
3 months ago
by
Brian Callaghan, MD, MS

1:02
Diagnosis Is Not the Same as Treatment in Multiple Sclerosis
3 months ago
by
Daniel Ontaneda, MD, PhD(+1 more)

1:46
How Biomarkers Can Help Clarify the MS Diagnostic Gray Zone
3 months ago
by
Daniel Ontaneda, MD, PhD(+1 more)

1:17
RECAP: Neurology News Network - July 4th
3 months ago
by
Louie Pasculli

0:56
Debunking Nerve Pain Myths
3 months ago
by
Mitzi Joi Williams, MD

2:00
Incorporating Biomarkers as Clinical End Points in Nerve Disorder Trials
3 months ago
by
Brett Morrison, MD, PhD

2:07
MicroRNAs Emerge as Promising Biomarkers for Diabetic Neuropathy
3 months ago
by
Brett Morrison, MD, PhD

1:39
RECAP: Neurology News Network - June 27th
3 months ago
by
Louie Pasculli

2:06
SLEEP 2026: Media Training Workshop on Sleep Science
3 months ago
by
Julie Flygare, JD(+1 more)

1:03
ATMRD 2026: Understanding Demoralization in Parkinson Disease
3 months ago
by
Indu Subramanian, MD(+1 more)
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Tavapadon for the Treatment of Parkinson Disease
2
FDA Accepts Fenebrutinib NDA Under Priority Review for Relapsing and Primary Progressive MS
3
ADHERE REAL Study to Assess Real-World Effectiveness of Efgartigimod in CIDP
4
Phase 4 OCTAGON Trial to Test Rapid Steroid Taper With Ravulizumab
5
